RNAZ — Transcode Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Transcode Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.84 | -17.6 | -18.5 | -16.8 | -34.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.13 | 0.365 | 1.43 | 3.68 | 15.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.402 | 1.34 | -1.08 | -0.351 | -0.211 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -5.27 | -15.8 | -18.1 | -13.3 | -19.5 |
| Capital Expenditures | -0.255 | -0.101 | -0.036 | -0.022 | -0.007 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.003 | 0 | — | — | 0.002 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.252 | -0.101 | -0.036 | -0.022 | -0.004 |
| Financing Cash Flow Items | -0.832 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 25.5 | 0.006 | 15.9 | 16.4 | 31.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20 | -15.9 | -2.2 | 3.04 | 12 |